XML 74 R45.htm IDEA: XBRL DOCUMENT
v3.22.1

Assets and liabilities from subsidiaries held for sale and discontinued operations (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2021
Assets and liabilities from subsidiaries held for sale and discontinued operations |
Schedule of impairment loss allocation to assets |
| Amount |
Goodwill | 68,273 |
Residual surplus value of fixed assets | 160 |
Intangibles assets arising from business combination | 76,136 |
Property, plant, and equipment | 60,548 |
Right-of-use assets | 38,957 |
Recoverable taxes | 183,455 |
Impairment | 427,529 |
Deferred income and social contribution taxes | (145,360 | )
Net impairment | 282,169 |
Schedule of classes of assets and liabilities classified as held for sale |
Liabilities | Oxiteno |  |  | Extrafarma |  |  | Eliminations (*) |  |  | Total |
Current liabilities |  |  |  |  |  |  |  |  |  |  |
Loans, financing and hedge derivative financial instruments | 302,154 |  |  | ‐ |  |  | (62,841 | ) |  | 239,313 |
Trade payables | 493,800 |  |  | 225,487 |  |  | (1,949 | ) |  | 717,338 |
Trade payables – reverse factoring | 725,246 |  |  | - |  |  | - |  |  | 725,246 |
Salaries and related charges | 176,941 |  |  | 45,843 |  |  | - |  |  | 222,784 |
Taxes payables | 53,988 |  |  | 15,696 |  |  | - |  |  | 69,684 |
Income and social contribution taxes payable | 12,415 |  |  | ‐ |  |  | ‐ |  |  | 12,415 |
Post-employment benefits | 3,311 |  |  | - |  |  | - |  |  | 3,311 |
Provision for tax, civil, and labor risks | 2,946 |  |  | 520 |  |  | - |  |  | 3,466 |
Leases payable | 11,702 |  |  | 64,312 |  |  | - |  |  | 76,014 |
Other liabilities | 68,721 |  |  | 13,249 |  |  | (13,264 | ) |  | 68,706 |
Total current liabilities | 1,851,224 |  |  | 365,107 |  |  | (78,054 | ) |  | 2,138,277 |
Non-current liabilities |  |  |  |  |  |  |  |  |  |  |
Loans, financing and hedge derivative financial instruments | 5,728,028 |  |  | ‐ |  |  | (5,725,594 | ) |  | 2,434 |
Related parties | 2,875 |  |  | ‐ |  |  | (2,875 | ) |  | ‐ |
Deferred income and social contribution taxes | 12,964 |  |  | ‐ |  |  | ‐ |  |  | 12,964 |
Post-employment benefits | 6,806 |  |  | 287 |  |  | - |  |  | 7,093 |
Provision for tax, civil, and labor risks | 33,149 |  |  | 2,370 |  |  | - |  |  | 35,519 |
Leases payable | 22,786 |  |  | 314,915 |  |  | - |  |  | 337,701 |
Other liabilities | 5,341 |  |  | 2,092 |  |  | - |  |  | 7,433 |
Total non-current liabilities | 5,811,949 |  |  | 319,664 |  |  | (5,728,469 | ) |  | 403,144 |
Total equity | 1,824,337 |  |  | 857,392 |  |  | (2,681,729 | ) |  | - |
Total liabilities held for sale and equity | 9,487,510 |  |  | 1,542,163 |  |  | (8,488,252 | ) |  | 2,541,421 |
(*) Balances and transactions between the discontinued and continuing operations have been eliminated, mainly related to loans.
Assets | Oxiteno |  |  | Extrafarma |  |  | Eliminations (*) |  |  | Total |
Current assets |  |  |  |  |  |  |  |  |  |  |
Cash and cash equivalents | 334,882 |  |  | 53,099 |  |  | ‐ |  |  | 387,981 |
Financial investments and hedging instruments | 1,346,552 |  |  | ‐ |  |  | ‐ |  |  | 1,346,552 |
Trade receivables | 993,960 |  |  | 35,743 |  |  | ‐ |  |  | 1,029,703 |
Inventories | 1,671,662 |  |  | 578,206 |  |  | ‐ |  |  | 2,249,868 |
Recoverable taxes | 634,718 |  |  | 62,053 |  |  | ‐ |  |  | 696,771 |
Other assets | 51,829 |  |  | 26,145 |  |  | (5,035 | ) |  | 72,939 |
Total current assets | 5,033,603 |  |  | 755,246 |  |  | (5,035 | ) |  | 5,783,814 |
Non-current assets |  |  |  |  |  |  |  |  |  |  |
Financial investments and hedging instruments | 492,430 |  |  | ‐ |  |  | ‐ |  |  | 492,430 |
Related parties | ‐ |  |  | 1,674 |  |  | (1,674 | ) |  | ‐ |
Deferred income and social contribution taxes | 541,756 |  |  | 200,194 |  |  | ‐ |  |  | 741,950 |
Recoverable taxes | 393,723 |  |  | 17,938 |  |  | ‐ |  |  | 411,661 |
Other assets | 10,538 |  |  | 4,136 |  |  | ‐ |  |  | 14,674 |
| 1,438,447 |  |  | 223,942 |  |  | (1,674 | ) |  | 1,660,715 |
Investments | 36,207 |  |  | 5,000 |  |  | (22,047 | ) |  | 19,160 |
Right-of-use assets, net | 31,871 |  |  | 318,183 |  |  | ‐ |  |  | 350,054 |
Property, plant, and equipment | 2,787,241 |  |  | 154,663 |  |  | ‐ |  |  | 2,941,904 |
Intangible assets | 160,141 |  |  | 85,129 |  |  | ‐ |  |  | 245,270 |
Total non-current assets | 4,453,907 |  |  | 786,917 |  |  | (23,721 | ) |  | 5,217,103 |
Total assets held for sale | 9,487,510 |  |  | 1,542,163 |  |  | (28,756 | ) |  | 11,000,917 |
(*) Balances and transactions between the discontinued and continuing operations have been eliminated, mainly related to loans. c.1 The main classes of assets and liabilities classified as held for sale on December 31, 2021 are shown below:
Schedule of profit (loss) for the year and cash flows from discontinued operations | c.2 The results for the year and cash flows from discontinued operations as of December 31, 2021 are shown below:
| Oxiteno |  |  | Extrafarma |  |  | Eliminations (*) |  |  | Total |
Net revenue from sales and services | 7,102,771 |  |  | 1,986,932 |  |  | (23,908 | ) |  | 9,065,795 |
Cost of products and services sold | (5,540,773 | ) |  | (1,384,316 | ) |  | 23,908 |  |  | (6,901,181 | )
Gross profit | 1,561,998 |  |  | 602,616 |  |  | ‐ |  |  | 2,164,614 |
Operating income (expenses) |  |  |  |  |  |  |  |  |  |  |
Selling marketing and administrative | (978,221) |  |  | (685,794 | ) |  | ‐ |  |  | (1,664,015 | )
Impairment | ‐ |  |  | (427,529 | ) |  | ‐ |  |  | (427,529 | )
Other operating income, net | 26,924 |  |  | (1,109 | ) |  | ‐ |  |  | 25,815 |
Operating income (loss) before finance income (expenses) and share of profit of associates | 610,701 |  |  | (511,816 | ) |  | ‐ |  |  | 98,885 |
Share of profit of associates | 48 |  |  | ‐ |  |  | - |  |  | 48 |
Operating income (loss) before finance income (expenses) and income and social contribution taxes | 610,749 |  |  | (511,816 | ) |  | - |  |  | 98,933 |
Financial result, net | (431,441 | ) |  | (45,265 | ) |  | 329,736 |  |  | (146,970 | )
Profit (loss) before income and social contribution taxes | 179,308 |  |  | (557,081 | ) |  | 329,736 |  |  | (48,037 | )
Income and social contribution taxes | 69,995 |  |  | 155,416 |  |  | (112,110 | ) |  | 113,301 |
Profit (loss) for the year | 249,303 |  |  | (401,665 | ) |  | 217,626 |  |  | 65,264 |
Deprecia tion and amortiza tion for the year (i) | 308,564 |  |  | 154,850 |  |  | - |  |  | 463,414 |
(*) Elimination between continuing and discontinued operations related to the intercompany loan (PPE) between Ultrapar International and Oxiteno. (i) Balances included for complete breakdown of segment information.
| Oxiteno |  |  | Extrafarma |  |  | Eliminations |  |  | Total |
Net cash provided by (used in) operating activities | 1,016,580 |  |  | (33,273 | ) |  | (788 | ) |  | 982,519 |
Net cash used in investing activities | (122,363 | ) |  | (35,072 | ) |  | (1,298 | ) |  | (158,733 | )
Net cash provided by (used in) financing activities | (1,054,930 | ) |  | 35,286 |  |  | 466,677 |  |  | (552,967 | )
Effect of exchange rate changes on cash and cash equivalents in foreign currency | 56,553 |  |  | ‐ |  |  | ‐ |  |  | 56,553 |
(Decrease) increase in cash and cash equivalents | (104,160 | ) |  | (33,059 | ) |  | 464,591 |  |  | 327,372 |
c.3 The results for the year and cash flows from discontinued operations as of December 31, 2020 are shown below:
| 12/31/2020 |  |  | Discontinued operations |  |  | 12/31/2020 |
| Disclosed |  |  | Oxiteno |  |  | Extrafarma |  |  | Eliminations |  |  | Total |  |  | Re-Restated |
Net revenue from sales and services | 81,241,102 |  |  | 5,210,704 |  |  | 1,988,411 |  |  | (16,069 | ) |  | 7,183,046 |  |  | 74,058,056 |
Cost of products and services sold | (75,628,214 | ) |  | (4,188,711 | ) |  | (1,399,125 | ) |  | 16,069 |  |  | (5,571,767 | ) |  | (70,056,447 | )
Gross profit | 5,612,888 |  |  | 1,021,993 |  |  | 589,286 |  |  | ‐ |  |  | 1,611,279 |  |  | 4,001,609 |
Operating income (expenses) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Selling marketing and administrative | (4,098,377 | ) |  | (831,056 | ) |  | (662,182 | ) |  | - |  |  | (1,493,238 | ) |  | (2,605,139 | )
Other operating income, net | 297,544 |  |  | 153,457 |  |  | (5,403 | ) |  | - |  |  | 148,054 |  |  | 149,490 |
Operating income (loss) before finance income (expenses) and share of profit (loss) of subsidiaries, joint ventures and associates | 1,812,055 |  |  | 344,394 |  |  | (78,299) |  |  | ‐ |  |  | 266,095 |  |  | 1,545,960 |
Share of profit (loss) of subsidiaries, joint ventures and associates | (43,617 | ) |  | 414 |  |  | ‐ |  |  | - |  |  | 414 |  |  | (44,031 | )
Operating income (loss) before finance income (expenses) and income and social contribution taxes | 1,768,438 |  |  | 344,808 |  |  | (78,299 | ) |  | - |  |  | 266,509 |  |  | 1,501,929 |
Financial result, net | (269,374 | ) |  | 1,482 |  |  | (38,938 | ) |  | 318,430 |  |  | 280,974 |  |  | (550,348 | )
Profit (loss) before income and social contribution taxes | 1,499,064 |  |  | 346,290 |  |  | (117,237 | ) |  | 318,430 |  |  | 547,483 |  |  | 951,581 |
Income and social contribution taxes | (571,367 | ) |  | (118,132 | ) |  | (40,453 | ) |  | (108,265 | ) |  | (266,850 | ) |  | (304,517 | )
Net income from continuing operations | - |  |  | - |  |  | - |  |  | - |  |  | - |  |  | 647,064 |
Net income from discontinued operations | - |  |  | - |  |  | - |  |  | - |  |  | 280,633 |  |  | 280,633 |
Profit (loss) for the year | 927,697 |  |  | 228,158 |  |  | (157,690 | ) |  | 210,165 |  |  | 280,633 |  |  | 927,697 |
Deprecia tion and amortiza tion for the year (i) | 1,556,599 |  |  | 275,063 |  |  | 153,899 |  |  | - |  |  | 428,962 |  |  | 1,127,637 |
(i) Balances included for complete breakdown of segment information.
| 12/31/2020 |  |  | Discontinued operations |  | 12/31/2020 |
| Disclosed |  |  | Oxiteno |  |  | Extrafarma |  |  | Eliminations |  |  | Total |  |  | Re-Restated |
| (A) |  |  |  |  |  |  |  |  |  |  |  | (B) |  |  | (A-B) |
Net cash provided by (used in) operating activities | 3,138,119 |  |  | 765,090 |  |  | 111,396 |  |  | (2,380 | ) |  | 874,106 |  |  | 2,264,013 |
Net cash used in investing activities | (2,136,405 | ) |  | (159,349 | ) |  | (6,484 | ) |  | (321,557 | ) |  | (487,390 | ) |  | (1,649,015 | )
Net cash (used in) provided by financing activities | (592,333 | ) |  | (1,236,490 | ) |  | 11,272 |  |  | 305,534 |  |  | (919,684 | ) |  | 327,351 |
Effect of exchange rate changes on cash and cash equivalents in foreign currency | 136,734 |  |  | 114,822 |  |  | ‐ |  |  | ‐ |  |  | 114,822 |  |  | 21,912 |
Increase (decrease) in cash and cash equivalents | 546,115 |  |  | (515,927 | ) |  | 116,184 |  |  | (18,403) |  |  | (418,146 | ) |  | 964,261 |
c.4 The results for the year and cash flows from discontinued operations as of December 31, 2019 are shown below:
| 12/31/2019 |  |  | Discontinued operations |  |  | 12/31/2019 |
| Disclosed |  |  | Oxiteno |  |  | Extrafarma |  |  | Eliminations |  |  | Total |  |  | Re-Restated |
Net revenue from sales and services | 89,297,975 |  |  | 4,254,237 |  |  | 2,060,569 |  |  | (21,560 | ) |  | 6,293,246 |  |  | 83,004,729 |
Cost of products and services sold | (83,187,109 | ) |  | ( 3,537,570 | ) |  | (1,462,313 | ) |  | 21,560 |  |  | ( 4,978,323 | ) |  | (78,208,786 | )
Gross profit | 6,110,866 |  |  | 716,667 |  |  | 598,256 |  |  | - |  |  | 1,314,923 |  |  | 4,795,943 |
Operating income (expenses) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Selling marketing and administrative | ( 4,366,640 | ) |  | ( 737,606 | ) |  | (742,599 | ) |  | - |  |  | ( 1,480,205 | ) |  | ( 2,886,435 | )
Other operating income, net | (443,674 | ) |  | (5,348 | ) |  | (580,055 | ) |  | - |  |  | ( 585,403 | ) |  | 141,729 |
Operating income (loss) before finance income (expenses) and share of profit (loss) of subsidiaries, joint ventures and associates | 1,300,552 |  |  | (26,287 | ) |  | (724,398 | ) |  | - |  |  | (750,685 | ) |  | 2,051,237 |
Share of profit (loss) of subsidiaries, joint ventures and associates | (12,145 | ) |  | 528 |  |  | - |  |  | 36 |  |  | 564 |  |  | ( 12,709 | )
Operating income (loss) before finance income (expenses) and income and social contribution taxes | 1,288,407 |  |  | (25,759 | ) |  | (724,398 | ) |  | 36 |  |  | (750,121 | ) |  | 2,038,528 |
Financial result, net | (506,854 | ) |  | 14,464 |  |  | (32,451 | ) |  | (184,484 | ) |  | 166,497 |  |  | ( 673,351 | )
Profit (loss) before income and social contribution taxes | 781,553 |  |  | (11,295 | ) |  | (756,849 | ) |  | 184,520 |  |  | (583,624 | ) |  | 1,365,177 |
Income and social contribution taxes | (378,609 | ) |  | 35,191 |  |  | 118,901 |  |  | (62,725 | ) |  | 91,367 |  |  | (469,976 | )
Net income from continuing operations | 402,944 |  |  | 23,896 |  |  | ( 637,948 | ) |  | 121,795 |  |  | ( 492,257 | ) |  | 895,201 |
Net income from discontinued operations | - |  |  | (23,896 | ) |  | 637,948 |  |  | (121,795 | ) |  | 492,257 |  |  | ( 492,257 | )
Profit (loss) for the year | 402,944 |  |  | - |  |  | - |  |  | - |  |  | - |  |  | 402,944 |
Depreciation and amortization for the year (1) | 1,499,955 |  |  | 222,004 |  |  | 154,324 |  |  | - |  |  | 376,328 |  |  | 1,123,627 |
(i) Balances included for complete breakdown of segment information.
| 12/31/2019 |  |  | Discontinued operations |  | 12/31/2019 |
| Disclosed |  |  | Oxiteno |  |  | Extrafarma |  |  | Eliminations |  |  | Total |  |  | Re-Restated |
| (A) |  |  |  |  |  |  |  |  |  |  |  | (B) |  |  | (A-B) |
Net cash provided by (used in) operating activities | 2,924,852 |  |  | 486,276 |  |  | 23,282 |  |  | 42,910 |  |  | 552,468 |  |  | 2,372,384 |
Net cash used in investing activities | (1,835,261 | ) |  | (882,894 | ) |  | (122,462 | ) |  | 9,433 |  |  | (995,923 | ) |  | (839,338 | )
Net cash (used in) provided by financing activities | (2,922,229 | ) |  | (375,258 | ) |  | 125,852 |  |  | 7,499 |  |  | (241,907 | ) |  | (2,680,322 | )
Effect of exchange rate changes on cash and cash equivalents in foreign currency | 9,066 |  |  | 30,871 |  |  | - |  |  | - |  |  | 30,871 |  |  | (21,805 | )
Increase (decrease) in cash and cash equivalents | (1,823,572 | ) |  | (741,005 | ) |  | 26,672 |  |  | 59,842 |  |  | (654,491 | ) |  | (1,169,081 | )

X
- Definition The disclosure of the analysis of the single amount of discontinued operations. [Refer: Discontinued operations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 5 -IssueDate 2021-01-01 -Paragraph 33 -Subparagraph b -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2021-en-r&anchor=para_33_b&doctype=Standard -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfAnalysisOfSingleAmountOfDiscontinuedOperationsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the impairment of assets. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 36 -IssueDate 2021-01-01 -Section Disclosure -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=36&code=ifrs-tx-2021-en-r&doctype=Standard&dita_xref=IAS36_g126-137_TI -URIDate 2021-03-24 + Details
Name: | ifrs-full_DisclosureOfImpairmentOfAssetsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_NoncurrentAssetsOrDisposalGroupsClassifiedAsHeldForSaleOrAsHeldForDistributionToOwnersAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of assets and liabilities or disposal groups classified as held for sale. + References No definition available. + Details
Name: | ugp_DisclosureOfAssetsAndLiabilitiesOrDisposalGroupsClassifiedAsHeldForSaleExplanatory
Namespace Prefix: | ugp_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration